Find Businesses & Services
Angstrom Pharmaceuticals Inc in San Diego, California
Company Description:
Angstrom is conducting a Phase 2 clinical trial for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Services Offered:
Pharmaceutical Consultants
Drug Stores And Proprietary Stores
Web Results:
- The Urokinase/Urokinase...
- Home Management Advisors Drug Programs Clinical Trials Patents Press Releases Publications Contact Us Investigative Ophthalmology and Visual Science 44, 2736-2742, June 2003 The Urokinase/Urokinase Receptor System in Retinal Neovascularization: Inhibition by A6 Suggests a New Therapeutic Target McGu...
- Clinical Trials
- Home Management Advisors Drug Programs Clinical Trials Patents Press Releases Publications Contact Us Clinical Trials A Phase 2 Trial to Determine the Safety, Tolerability, and Efficacy of 6, a CD44 Binding Peptide, for the Treatment of Patients with Chronic Lymphocytic Leukemia. Purpose: This stud...
- The Urokinase Plasminogen...
- Home Management Advisors Drug Programs Clinical Trials Patents Press Releases Publications Contact Us Journal Articles Recent Res. Devel. Cancer, 2 (2000): 1-12 The Urokinase Plasminogen Activator Receptor (uPAR) is a Chokepoint for Carcinoma Metastasis and Angiogenesis Andrew P. Mazar, Susan Gawlak...
- Patents
- Home Management Advisors Drug Programs Clinical Trials Patents Press Releases Publications Contact Us Patents Proprietary Position Worldwide, ngstrom holds 35 granted patents with 3 applications pending. The patents cover composition-of-matter, pharmaceutical compositions, and methods of use for 6 a...
- The Urokinase Plasminogen...
- Home Management Advisors Drug Programs Clinical Trials Patents Press Releases Publications Contact Us Angiogenesis , 3 (1) 15 (1999) The Urokinase Plasminogen Activator System in Cancer: Implications for tumor angiogenesis and metastasis Andrew P. Mazar, Jack Henkin and Ronald H. Goldfarb Substantia...
Business Information:
| Business Sector: | Residential, Commercial |
Related Categories:
Website Links:
Angstrom Pharmaceuticals Inc | 6 peptide activates CD44... | An Antiangiogenic Urokinase-derived... | A phase 2, randomized,... | A Peptide Derived from... | Patents | A Three-Dimensional and... | Advisors | The Urokinase Plasminogen... | Selective Cytotoxicity... | 6, a urokinase plasminogen... | Drug Programs | Safety, Tolerability,... | Inhibition of choroidal... | The Urokinase/Urokinase... | A Urokinase-Derived Peptide... | A peptide inhibitor of... | Clinical Trials
Found any discrepancies in your company profile?
Request to update the information